
Sign up to save your podcasts
Or
In this interview, Spencer King and Marc Bonaca discuss insights from the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial, specifically dapagliflozin and outcomes in patients with peripheral artery disease.
3.7
5353 ratings
In this interview, Spencer King and Marc Bonaca discuss insights from the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial, specifically dapagliflozin and outcomes in patients with peripheral artery disease.
131 Listeners
325 Listeners
161 Listeners
865 Listeners
496 Listeners
281 Listeners
3,336 Listeners
90 Listeners
138 Listeners
1,095 Listeners
39 Listeners
185 Listeners
349 Listeners
427 Listeners
37 Listeners